Innoviva, Inc. (NASDAQ:INVA) Citi’s Biopharma Back to School Conference September 2, 2025 1:45 PM EDT
Company Participants
Pavel Raifeld – CEO & Director
Conference Call Participants
Jason Jun – Citi
Presentation
Jason Jun
Well, thanks for joining, everyone. Today with us, we have Pavel Raifeld, the CEO of Innoviva. Pavel, thank you for joining us today. My name is Jason Jun, Managing Director on the Biopharma Banking team at Citi. So here today for Innoviva’s fireside chat. So Pavel, thanks for joining us.
Pavel Raifeld
CEO & Director
Thank you, Jason, for hosting us.
Question-and-Answer Session
Jason Jun
Great. So Pavel, why don’t we just get started with a quick overview of the company and I think specifically, if you wouldn’t mind just walking us through the three business pillars at a high level, we can start there.
Pavel Raifeld
CEO & Director
Sure. That sounds wonderful. And once again, thank you for the opportunity to present the Innoviva story. First, I think it will be helpful to start with some background information on how the company was formed. Innoviva was originally founded to manage royalty revenues for products that we developed with and licensed to GSK. And as the royalty revenues for these products, Breo and Anoro, became more meaningful over time, we decided to build out other areas of the business in an effort to create long-term value for our shareholders.
And so as a result, Innoviva right now is composed of three business areas to which you alluded earlier. The first is a steady royalty stream from two widely used and highly differentiated respiratory products marketed by GSK. The second is a fast-growing critical care and infectious disease platform that we refer to as Innoviva Specialty Therapeutics, or IST, which includes four commercial stage products that are growing at over
#Innoviva #INVA #Presents #Citis #Biopharma #School #Conference #Transcript